GO:1990667 PCSK9-AnxA2 complex: Components, Assembly and Research Methods, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1990667 defines the PCSK9-AnxA2 complex, a cellular component consisting of the serine protease PCSK9 and annexin A2 (AnxA2).
• The complex is implicated in cholesterol homeostasis, inflammation, and cancer progression through PCSK9-mediated degradation of LDLR and AnxA2-dependent membrane repair.
• PCSK9 gain-of-function mutations cause autosomal dominant hypercholesterolemia, while loss-of-function variants are protective.
• AnxA2 is a calcium-dependent phospholipid-binding protein involved in membrane organization, endocytosis, and exocytosis.
• Experimental models for studying the complex include CRISPR knockout, point-mutation knock-in, and overexpression cell lines.
• EDITGENE provides custom CRISPR services to interrogate PCSK9-AnxA2 complex biology in relevant cell models.
Description
The PCSK9-AnxA2 complex (GO:1990667) is a cellular component defined by the physical association between proprotein convertase subtilisin/kexin-9 (PCSK9) and annexin A2 (AnxA2). This complex has garnered attention due to its roles in lipid metabolism, inflammation, and cancer. PCSK9 is a secreted serine protease that regulates plasma cholesterol by promoting degradation of the low-density lipoprotein receptor (LDLR). AnxA2 is a multifunctional calcium-dependent phospholipid-binding protein that participates in membrane trafficking, cell adhesion, and signal transduction. The interaction between PCSK9 and AnxA2 may modulate these processes, offering a potential target for therapeutic intervention. Understanding the PCSK9-AnxA2 complex is essential for researchers studying cardiovascular disease, metabolic disorders, and tumor biology.
PCSK9-AnxA2 complex At A Glance
| GO ID | GO:1990667 |
|---|---|
| GO term | PCSK9-AnxA2 complex |
| Ontology | cellular_component |
| Synonym | PCSK9-Annexin A2 complex; PCSK9.AnxA2 complex; PCSK9:ANXA2 complex |
| Major function | Mediates PCSK9-dependent regulation of LDLR and AnxA2-related membrane dynamics |
| Components | PCSK9 (serine protease) and AnxA2 (calcium-dependent phospholipid-binding protein) |
| Associated diseases | Hypercholesterolemia, cardiovascular disease, cancer |
| Research models | CRISPR knockout/knock-in cell lines, overexpression systems |
What Is GO:1990667?
According to QuickGO, GO:1990667 (PCSK9-AnxA2 complex) is a protein complex consisting of the serine protease PCSK9 (proprotein convertase subtilisin/kexin-9) and annexin A2 (AnxA2). This definition implies a stable or transient physical interaction between these two proteins, forming a functional unit within the cell.
Why Is PCSK9-AnxA2 complex Important in Cell Biology?
The PCSK9-AnxA2 complex is important because it links two key pathways: cholesterol homeostasis via PCSK9 and membrane/cytoskeletal regulation via AnxA2. Dysregulation of PCSK9 is a well-established cause of familial hypercholesterolemia, and AnxA2 is implicated in cancer progression and inflammation. Thus, the complex represents a potential node for therapeutic intervention in cardiovascular and oncological diseases.
• PCSK9 is a validated drug target for lowering LDL cholesterol; understanding its interaction with AnxA2 may reveal new regulatory mechanisms.
• AnxA2 is involved in membrane repair, endocytosis, and exocytosis, processes that could be modulated by PCSK9 binding.
• The complex may influence inflammatory signaling, as both proteins have roles in immune responses.
• In cancer, AnxA2 promotes cell migration and invasion; PCSK9 may affect these processes through complex formation.
• Genetic variants in PCSK9 affect LDLR degradation; AnxA2 might modulate this function.
• The complex could serve as a biomarker or therapeutic target in metabolic and cardiovascular diseases.
• Studying the complex helps elucidate cross-talk between lipid metabolism and membrane trafficking.
• CRISPR-based models enable precise dissection of the complex's function in health and disease.
Structure and Composition of PCSK9-AnxA2 complex
PCSK9: The Serine Protease Component
In simple terms: PCSK9 is an enzyme that helps control cholesterol levels by breaking down LDL receptors.
PCSK9 (proprotein convertase subtilisin/kexin-9) is a secreted serine protease primarily known for its role in LDL receptor degradation. It contains a prodomain, catalytic domain, and C-terminal domain. PCSK9 is synthesized as a zymogen and undergoes autocatalytic processing. Its interaction with AnxA2 may occur intracellularly or at the cell surface.
AnxA2: The Calcium-Dependent Phospholipid-Binding Protein
In simple terms: AnxA2 is a protein that binds to cell membranes in a calcium-dependent manner and helps organize membrane events.
Annexin A2 (AnxA2) is a member of the annexin family, characterized by calcium-dependent binding to negatively charged phospholipids. It exists as a monomer or heterotetramer with S100A10. AnxA2 is involved in membrane repair, endocytosis, exocytosis, and actin cytoskeleton organization. Its interaction with PCSK9 may influence these functions.
Assembly and Stoichiometry
In simple terms: The complex forms when PCSK9 and AnxA2 physically bind to each other.
The PCSK9-AnxA2 complex is thought to assemble through direct protein-protein interactions, potentially mediated by the catalytic domain of PCSK9 and the annexin core domain of AnxA2. The stoichiometry and affinity of the complex are not fully characterized, but it may be a transient interaction regulated by cellular conditions.
Subcellular Localization
In simple terms: The complex can be found in different parts of the cell, depending on the cell type and conditions.
PCSK9 is primarily secreted but also found in the endoplasmic reticulum, Golgi, and endosomes. AnxA2 localizes to the plasma membrane, endosomes, and nucleus. The complex may form at the plasma membrane or in endocytic compartments, influencing LDLR trafficking and membrane dynamics.
Key Genes Involved in GO:1990667 PCSK9-AnxA2 complex
The following genes and proteins are key players in the biology of the PCSK9-AnxA2 complex.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PCSK9 | Serine protease that promotes LDLR degradation | Target for hypercholesterolemia therapy; interacts with AnxA2 |
| ANXA2 | Calcium-dependent phospholipid-binding protein | Involved in membrane repair, cancer progression; binds PCSK9 |
| LDLR | Low-density lipoprotein receptor | Mediates cholesterol uptake; degraded by PCSK9 |
| S100A10 | Annexin A2 binding partner | Forms heterotetramer with AnxA2; may modulate complex |
| ARH | Adaptor protein for LDLR endocytosis | Facilitates LDLR internalization; potential crosstalk |
| IDOL | E3 ubiquitin ligase for LDLR | Alternative pathway for LDLR degradation |
| MYLIP | E3 ubiquitin ligase | Regulates LDLR stability |
| HMGCR | Rate-limiting enzyme in cholesterol synthesis | Feedback regulation by cholesterol |
| SREBF2 | Transcription factor for cholesterol genes | Regulates PCSK9 and LDLR expression |
| NPC1L1 | Intestinal cholesterol absorption | Target of ezetimibe; potential interplay |
| ABCA1 | Cholesterol efflux transporter | HDL biogenesis; may affect membrane composition |
| APOB | Apolipoprotein B | Component of LDL; affects PCSK9 levels |
| APOE | Apolipoprotein E | Lipid transport; influences cardiovascular risk |
| CETP | Cholesteryl ester transfer protein | Modulates HDL/LDL ratio |
| LPA | Lipoprotein(a) | Independent cardiovascular risk factor |
| TNF | Pro-inflammatory cytokine | May regulate AnxA2 and PCSK9 expression |
| IL6 | Interleukin-6 | Inflammatory cytokine; affects PCSK9 expression |
How Is PCSK9-AnxA2 complex Regulated?
The expression and activity of the PCSK9-AnxA2 complex are regulated at multiple levels. PCSK9 transcription is controlled by SREBP-2 in response to cellular cholesterol levels. AnxA2 expression can be induced by inflammatory cytokines such as TNF and IL-6. Post-translational modifications, including phosphorylation and calcium binding, regulate AnxA2 function. The interaction between PCSK9 and AnxA2 may be modulated by calcium signaling and membrane lipid composition.
PCSK9-AnxA2 complex and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PCSK9 | Hypercholesterolemia, cardiovascular disease | CRISPR knockout in HepG2 cells |
| ANXA2 | Cancer progression, inflammation | Knockout in HeLa or MDA-MB-231 cells |
| LDLR | Familial hypercholesterolemia | Point mutation knock-in in iPSCs |
| S100A10 | Cancer, membrane dynamics | Overexpression in HEK293T cells |
| TNF | Inflammation | CRISPR activation in macrophages |
Cardiovascular Disease and Hypercholesterolemia
PCSK9 gain-of-function mutations cause autosomal dominant hypercholesterolemia by increasing LDLR degradation. The PCSK9-AnxA2 complex may influence this process, as AnxA2 could affect PCSK9 trafficking or activity. Targeting the complex might offer new therapeutic strategies for lowering LDL cholesterol.
Cancer
AnxA2 is overexpressed in many cancers and promotes cell migration, invasion, and metastasis. PCSK9 has been implicated in cancer cell proliferation and apoptosis. The PCSK9-AnxA2 complex could modulate oncogenic signaling pathways, making it a potential target for cancer therapy.
Inflammation and Immune Response
Both PCSK9 and AnxA2 play roles in inflammation. AnxA2 is involved in macrophage function and cytokine secretion. PCSK9 can modulate inflammatory responses in atherosclerosis. The complex may thus contribute to inflammatory diseases.
From PCSK9-AnxA2 complex-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does PCSK9-AnxA2 complex regulate LDLR degradation? | PCSK9 knockout HepG2 cells with AnxA2 overexpression |
| What is the role of AnxA2 in PCSK9 secretion? | AnxA2 knockout HEK293T cells |
| How do disease-associated PCSK9 mutations affect complex formation? | Point mutation knock-in of PCSK9 variants |
| Can the complex be targeted to reduce cholesterol? | Knock-in of tagged PCSK9 for interaction studies |
| Does the complex influence cancer cell migration? | AnxA2 knockout in MDA-MB-231 cells |
| What is the stoichiometry of the complex? | Overexpression of both proteins in HeLa cells |
How to Study the PCSK9-AnxA2 complex Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Co-IP | Protein-protein interaction | Confirm PCSK9-AnxA2 binding in cells |
| PLA | In situ protein interaction | Visualize complex in fixed cells |
| CRISPR screen | Gene function | Identify regulators of complex |
| Mass spectrometry | Protein identification | Discover novel complex components |
| Western blot | Protein expression | Assess knockout efficiency |
| qPCR | mRNA levels | Measure gene expression changes |
| Immunofluorescence | Protein localization | Determine subcellular distribution |
| Surface plasmon resonance | Binding affinity | Quantify PCSK9-AnxA2 interaction |
Co-Immunoprecipitation and Pull-Down Assays
Co-immunoprecipitation (co-IP) using antibodies against PCSK9 or AnxA2 can confirm the physical interaction in cell lysates. Pull-down assays with recombinant proteins can map binding domains.
Proximity Ligation Assay (PLA)
PLA allows in situ detection of the PCSK9-AnxA2 complex in fixed cells, providing spatial information.
CRISPR-Based Genetic Screens
Genome-wide CRISPR knockout screens can identify modifiers of PCSK9-AnxA2 complex function, such as regulators of LDLR levels.
Proteomics and Mass Spectrometry
Affinity purification coupled with mass spectrometry can identify additional components of the complex and post-translational modifications.
How CRISPR Can Be Used to Study GO:1990667 PCSK9-AnxA2 complex
Knockout
CRISPR knockout of PCSK9 or ANXA2 in cell lines such as HepG2 or HEK293T can abolish complex formation, enabling studies of its function in LDLR regulation and membrane dynamics.
Point Mutation
Introducing disease-associated point mutations (e.g., PCSK9 gain-of-function) via CRISPR knock-in allows precise modeling of hypercholesterolemia and assessment of complex formation.
Knock-in
Knock-in of epitope tags (e.g., FLAG, HA) into endogenous PCSK9 or ANXA2 loci facilitates endogenous complex purification and interaction studies.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression of PCSK9 and AnxA2 can amplify complex formation for biochemical assays.
How EDITGENE Supports PCSK9-AnxA2 complex Research
Researchers studying PCSK9-AnxA2 complex-related genes often need to determine whether a candidate gene is causally involved in complex formation, regulation, or downstream effects. EDITGENE provides a comprehensive suite of CRISPR-based services to enable such investigations.
Contact EDITGENE today to design your custom CRISPR model for PCSK9-AnxA2 complex research.
Frequently Asked Questions About PCSK9-AnxA2 complex
What is the PCSK9-AnxA2 complex?
The PCSK9-AnxA2 complex (GO:1990667) is a protein complex consisting of the serine protease PCSK9 and annexin A2 (AnxA2).
What genes are involved in the PCSK9-AnxA2 complex?
The complex is formed by PCSK9 and ANXA2 gene products.
What is the function of the PCSK9-AnxA2 complex?
It is thought to modulate PCSK9-mediated LDLR degradation and AnxA2-dependent membrane dynamics.
How is the PCSK9-AnxA2 complex studied?
Common methods include co-immunoprecipitation, proximity ligation assay, and CRISPR-based genetic screens.
What diseases are associated with the PCSK9-AnxA2 complex?
Cardiovascular disease, hypercholesterolemia, cancer, and inflammation.
Can CRISPR be used to study the PCSK9-AnxA2 complex?
Yes, CRISPR knockout, knock-in, and overexpression models enable functional dissection.
What is the GO ID for PCSK9-AnxA2 complex?
GO:1990667.
Where is the PCSK9-AnxA2 complex located in the cell?
It may localize to the plasma membrane, endosomes, or secretory pathway.
What are the synonyms for PCSK9-AnxA2 complex?
PCSK9-Annexin A2 complex, PCSK9.AnxA2 complex, PCSK9:ANXA2 complex.
How can EDITGENE help with PCSK9-AnxA2 complex research?
EDITGENE provides CRISPR knockout, knock-in, overexpression, library screening, and bioinformatics services.
Conclusion
The PCSK9-AnxA2 complex (GO:1990667) represents a fascinating intersection of lipid metabolism and membrane biology. Its components, PCSK9 and AnxA2, are individually well-studied, but their interaction opens new avenues for understanding cardiovascular and oncological diseases. Leveraging CRISPR technologies, researchers can now precisely manipulate these genes to uncover the complex's roles and therapeutic potential.
References
- 1. Bürmann F et al.. 2025. Mechanism of DNA capture by the MukBEF SMC complex and its inhibition by a viral DNA mimic.. Cell 188(9):2465-2479.e14 PMID: 40168993
